Mitsubishi UFJ Asset Management Co. Ltd. Buys 19,801 Shares of Cencora, Inc. $COR

Key Points

• Mitsubishi UFJ Asset Management boosted its stake in Cencora by 5.2%, buying 19,801 shares to hold 400,605 shares (about 0.21%) valued at roughly $135.75 million.
• Cencora raised FY2026 adjusted EPS guidance to $17.65–$17.90, authorized a $1 billion repurchase program and declared a $0.60 quarterly dividend, but Q2 EPS and revenue missed expectations and management trimmed revenue guidance, triggering a sharp selloff and a 52‑week low.

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 5.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 400,605 shares of the company's stock after acquiring an additional 19,801 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.21% of Cencora worth $135,753,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Vestcor Inc boosted its holdings in Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company's stock valued at $1,624,000 after acquiring an additional 28 shares in the last quarter. JFS Wealth Advisors LLC boosted its holdings in Cencora by 30.2% in the fourth quarter. JFS Wealth Advisors LLC now owns 125 shares of the company's stock valued at $42,000 after acquiring an additional 29 shares in the last quarter. Cornerstone Wealth Group LLC boosted its holdings in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company's stock valued at $745,000 after acquiring an additional 30 shares in the last quarter. Apollon Wealth Management LLC lifted its position in Cencora by 0.5% during the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company's stock valued at $2,205,000 after buying an additional 30 shares during the period. Finally, Vermillion & White Wealth Management Group LLC lifted its position in Cencora by 31.4% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company's stock valued at $43,000 after buying an additional 33 shares during the period. Institutional investors own 97.52% of the company's stock.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Company raised full‑year adjusted EPS guidance and authorized buyback — management bumped FY2026 adjusted EPS to $17.65–$17.90 and approved a $1 billion repurchase program, which supports shareholder returns and offsets some concerns about near‑term sales. Cencora raises annual profit forecast despite quarterly miss
• Positive Sentiment: Margin expansion and specialty wins — adjusted gross margins expanded ~45 bps, driven in part by the OneOncology integration and strong international operating income, signaling progress toward higher‑margin services. Cencora lifts 2026 outlook after OneOncology-fueled earnings jump
• Positive Sentiment: Quarterly dividend declared — board approved a $0.60 per‑share quarterly dividend (ex‑dividend May 15), modest yield but adds to cash return profile for income‑oriented shareholders.
• Neutral Sentiment: Top‑line growth but below expectations — revenue rose ~3.8% YoY to ~$78.4B, demonstrating underlying growth yet missing consensus and leaving investors focused on mix and client dynamics. Cencora Reports Fiscal 2026 Second Quarter Results
• Negative Sentiment: Earnings and revenue miss drove the selloff — adjusted EPS $4.75 missed expectations (~$4.80) and revenue missed estimates, prompting heavy investor selling and a sharp share decline. Cencora (COR) Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: Revenue guidance trimmed vs. Street — management’s revenue range came in below consensus, citing slower U.S. Healthcare Solutions sales, branded‑drug price cuts and lower volumes to a large mail‑order client. That downgrade to top‑line expectations is weighing on the stock. Cencora Shares Drop on Revenue Outlook Cut
• Negative Sentiment: Operational headwinds and market worries — reports note negative operating cash flow, customer losses, and margin pressure from GLP‑1 related mix; visible insider selling has also added to investor caution. Cencora Stock (COR) Opinions on Q2 Earnings Release
• Negative Sentiment: Technicals and sentiment: stock hit a fresh 52‑week low amid the reaction, increasing short‑term downside risk until clarity on U.S. segment recovery and cash‑flow stabilization. Cencora hits 52-week low after guidance cut

Cencora Price Performance

COR opened at $253.20 on Thursday. The stock has a 50-day moving average price of $330.01 and a 200-day moving average price of $342.75. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The firm has a market cap of $49.25 billion, a PE ratio of 30.43, a P/E/G ratio of 1.43 and a beta of 0.64. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts' expectations of $81.09 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.Cencora's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.58 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora's payout ratio is currently 28.85%.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They set a "market perform" rating for the company. Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Leerink Partners reissued an "outperform" rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, JPMorgan Chase & Co. raised their price objective on Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $398.17.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.